Daily dosing — Competitive Intelligence Brief

Daily dosing (Daily dosing) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Entry inhibitor. Area: Infectious Disease.

phase 2 Entry inhibitor HIV envelope glycoprotein Infectious Disease Small molecule

Target snapshot

Daily dosing (Daily dosing) — HIV Prevention Trials Network. This drug prevents HIV infection by blocking the virus's entry into host cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Daily dosing TARGET	Daily dosing	HIV Prevention Trials Network	phase 2	Entry inhibitor	HIV envelope glycoprotein
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)
FUZEON [enfuvirtide]	FUZEON [enfuvirtide]	Hoffmann-La Roche	marketed	HIV fusion inhibitor	gp41 (HIV envelope glycoprotein)
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)
Raxtozinameran 6 months to 4 years of age	raxtozinameran-6-months-to-4-years-of-age	Pfizer	marketed	viral entry inhibitor	SARS-CoV-2 virus
All licensed antiretroviral medications	All licensed antiretroviral medications	University of Minnesota	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Entry inhibitor class)

1. HIV Prevention Trials Network · 1 drug in this class